BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nie D, Fang Q, Li B, Cheng J, Li C, Gui S, Zhang Y, Zhao P. Research advances on the immune research and prospect of immunotherapy in pituitary adenomas. World J Surg Oncol 2021;19:162. [PMID: 34090476 DOI: 10.1186/s12957-021-02272-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang R, Zhou C, Mccormack AI, Mamelak AN. Editorial: Refractory Pituitary Adenoma—Current Challenges and Emerging Treatments. Front Endocrinol 2022;13:868174. [DOI: 10.3389/fendo.2022.868174] [Reference Citation Analysis]
2 Marques P, Silva AL, López-Presa D, Faria C, Bugalho MJ. The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications. Pituitary 2022. [PMID: 35194709 DOI: 10.1007/s11102-022-01211-5] [Reference Citation Analysis]
3 Nie D, Xue Y, Fang Q, Cheng J, Li B, Wang D, Li C, Gui S, Zhang Y, Zhao P. Immune Checkpoints: Therapeutic Targets for Pituitary Tumors. Dis Markers 2021;2021:5300381. [PMID: 34447484 DOI: 10.1155/2021/5300381] [Reference Citation Analysis]